As compared with patients with de novo disease, the care of patients with therapy-related myeloid malignancies, namely AML and the myelodysplastic syndromes (t-AML/MDS), is complicated by frequent comorbidities and reduced physiologic reserve combined with a malignancy that has a propensity for being recalcitrant to treatment. This disease behavior is reflected in this population by an overrepresentation of poor-risk cytogenetic features, including complex and monosomal karyotypes (chromosome 5 and/or 7 abnormalities), which are associated with refractoriness to conventional chemotherapies.
1
The estimated median survival of t-MDS/AML is a dismal 6-8 months, and allogeneic hematopoietic cell transplantation (HCT) is considered to be the only therapeutic modality to have a curative potential, or at least offer a long-term maintenance-free survival. 1 However, considering the fact that non-relapse morality can be high, and is amplified by comorbid conditions, HCT is often a tall order in this population. Depending on the latency period, patients with t-AML/MDS are on average older, and residual complications from prior therapies can lead to unacceptably high rates of transplant-related toxicity even with reduced-intensity conditioning (RIC).
From an epidemiological perspective, the disease burden of t-AML/MDS is rising, and is expected to continue to do so over the next several decades. A recent US Surveillance, Epidemiology, and End Results study of 426 000 adults treated for an initial primary malignancy between 1975 and 2008 showed a 4.7-fold increased risk of AML compared with the background incidence in the general population. 2 This phenomenon is largely due to major advances in therapies for primary malignancies that increase survival, thereby, leading to a growing pool of long-term cancer survivors, who because of their prior exposure to chemotherapy, radiation, or both are considered at risk for developing t-AML/ MDS. With this rising tide of cases over the coming years, and considering the high-risk nature of t-AML/MDS, increasing numbers of these patients are anticipated to undergo HCT. Therefore, there is a mounting need for contemporary, long-term outcomes data in this group.
Long-term survival data for MDS and AML patients is primarily derived from registry studies. Assuming the 'advanced AML' category in the Center for International Blood and Marrow Transplant Registry (CIBMTR) database captures all cases of t-AML, then the reported 3-year probabilities of overall survival (OS) for HLA-matched sibling or unrelated donor transplants are 27 ± 1% and 24 ± 1%, respectively, for these patients who underwent allogeneic HCT between 2003 and 2013. For the same time period, the corresponding figures for advanced MDS (assuming all t-MDS as advanced MDS) are 49 ± 1% and 39 ± 1%, for HLA-matched sibling and unrelated donor transplants, respectively.
3 Two large retrospective studies 4, 5 have specifically analyzed the outcomes of t-MDS/AML patients, highlighting inferior outcomes following allogeneic HCT. The CIBMTR conducted the largest t-MDS/AML study to date, reported on the outcomes of 323 t-MDS and 545 t-AML patients who underwent HCT between 1990 and 2004, noting a 5-year disease-free survival (DFS) and OS of 21% and 22%, respectively. 4 A contemporaneous study by the European Group for Blood and Marrow Transplantation (EBMT) including 461 patients with t-MDS/AML, reported a 3-year relapse-free and OS rates of 33% and 35%, respectively. 5 Though, in all these analyses, the definition of long-term survival was at best 5 years from the time of HCT due to limited follow-up.
In an article that accompanies this commentary, Finke et al. 6 reviewed the outcomes of their patients with the aim of filling that knowledge gap. They report on the long-term outcomes of 79 t-AML/MDS patients who underwent allogeneic HCT between 1995 and 2014 that were followed for a median of 7.5 years (0.07-19 years). 6 The cohort in this study was high risk based on several features: a median age of 58 years (35% over the age of 65 years), unfavorable cytogenetics (53%), HCT-comorbidity index (CI) score of 43 (77.2%) and induction failure with initial chemotherapy or progressive disease (42%).
Despite the limitations of a small, retrospective, singleinstitution study, there are several important findings not reported previously in this highly vulnerable population. To date, this is the longest known follow-up of patients who underwent transplantation for t-MDS/AML published, and demonstrates a remarkable 24% OS rate at 10 years, with a 5-year relapse rate of 42% that remained stable at 10 years. This study's relevance lies in the fact that the patient characteristics closely resembles the 'real-world' t-MDS/AML population seen in clinical practice today, and reflects the current allogeneic HCT practices-increasing use of RIC regimens and alternate donors. In comparison with prior t-MDS/AML studies, 4,5 the patients in this study were on average two decades older (median age, 58 vs 40 years), most received RIC regimens (~77%), and in general, a higher proportion had advanced disease at the time of transplantation. Despite this constellation of established poor prognostic factors, the study showed that a subset of t-MDS/AML patients can still experience long-term DFS. A principal question emerges from these findings: What biologic, disease-related and treatment-specific characteristics define these long-term survivors?
Several considerations need to be made when interpreting the findings from this and other t-AML/MDS studies. First and foremost, is the notion of what constitutes 'therapy-related. ' The etiology of an individual case of MDS or AML occurring after therapy for an unrelated primary malignancy cannot be attributed based solely on a binary assessment of leukemogenic exposure (yes or no) as defined in the current World Health Organization nomenclature. The definition of therapy-related has to be considered as a function of interaction among several covariates that include: age at exposure, time since prior therapy (that is, latency period), type and cumulative dose of chemotherapy, use of combined modality regimens (chemotherapy and radiation) and type of radiation modality (brachytherapy, involved field, TBI) that determines dose and volume of radiation delivered to the bone marrow. This has clinical implications as recent findings suggest that all therapy-related myeloid neoplasms (t-MN) are not necessarily high risk, therefore, should not be considered for upfront HCT. Two recent studies provide evidence that t-MNs following radiation monotherapy (for various primary malignancies) share cytogenetic characteristics with de novo disease and have similar survival (38 vs 30 months), raising the question of whether these cases are truly 'therapy-related.' 7, 8 In contrast, t-MN following treatment with chemotherapy alone or in combination with radiation is associated with an inferior OS, and a higher incidence of high-risk karyotypes, as compared with those treated definitively with radiotherapy-a subgroup where HCT would be indicated. 8 It is currently not possible to dissect these questions using registry data, as the reported outcomes of transplanted t-MDS/AML patients in the CIBMTR and EBMT is reflective of exposure to chemotherapy or combined modality therapies, considering 82% and 95% of the entire cohort in the registries received such treatment, respectively. 4, 5 Another consideration is the site and number of primary cancers, as well as the treatment-period effects. Registry data, that lack information on transplant, suggests that outcomes tend to be poor with t-MN occurring after two or more unrelated primaries as compared with one. 9 Using breast cancer as a reference, t-AML patients have worse outcomes following colorectal (Hazard ratio (HR) = 1.31; 1.14-1.5; P = 0.0002), or lung (HR = 1.46; 1.22-1.74; P o 0.0001) cancers, whereas t-MDS patients fared worse with prior lung (HR = 1.61; 1.22-2.12; P = 0.0007) or non-Hodgkin lymphoma (HR = 1.58; 1.3-92; P o0.0001). 9 It is plausible that the long-term survivors in the Finke study were comprised mainly of patients who were in CR at the time of HCT, had less leukemogenic exposure based on the type of primary malignancy, had favorable cytogenetics, or a combination of these factors that conferred a more favorable outcome. Moreover, epidemiologic data raise the possibility that a fair share of HCTs performed in so called t-MN may not truly be 'therapy-related.' Up to 80% of prostate cancer patients (leading cause of cancer in males) are eligible for definitive radiotherapy, with the corresponding figure in breast cancer (leading cancer in females) being 25%, mostly those with ductal carcinoma in situ. Together, these two primary cancers account for 40% (20% each) of the long-term cancer survivors in the United States and hence, the odds of subsequent t-MN occurring in these groups are proportionally higher. But based on recent data, the clinical course of t-MN in this primary cancer groups would be closer to de novo disease, thus these cases may do well with non-transplant approaches. The study by Finke et al. 6 does not elaborate on the characteristics of the long-term survivors with respect to the site and treatment of primary cancers.
Finally, recent molecular discoveries have identified several recurrent somatic mutations that have been shown to independently influence survival in both the non-transplant and transplant setting. 10 MDS patients harboring mutations in TP53 (HR, 4.22; P ≤ 0.001) and TET2 (HR, 1.68; P = 0.037) had 3-year posttransplant OS of 19% compared with 59% in those who did not have these mutations. 10 To what extent presence of these molecular mutations might have affected HCT outcomes in the University of Freiburg cohort is not known. The authors did not provide mutational data on these patients primarily because it was not being collected routinely in the 1990s and early 2000s. In conclusion, the study by Finke et al. 6 show that HCT is feasible and can be used successfully in a fraction of t-MDS/AML patients, and that improved outcomes will require efforts to base transplant decisions on newly available information, some of which will require validation in larger studies or through prospective trials.
